Industry News

• U.S. to provide antiviral medication to Latin America and the Caribbean for H1N1 influenza  HHS Secretary Kathleen Sebelius announced that the United States will provide 420,000 treatment courses of Tamiflu (Oseltamavir) to the Pan-American Health Organization (PAHO) to fight the novel H1N1 influenza in Latin America and the Caribbean.
  Dept. of Health & Human Services July 02, 2009  
• Oncolytics Biotech completes patient enrolment in U.K. REOLYSIN(R) trial  Oncolytics Biotech announced that patient enrolment has been completed in the Phase II component of a Phase I/II U.K. trial of REOLYSIN combined with paclitaxel/carboplatin for patients with advanced cancers.
  Oncolytics Biotech Inc. July 02, 2009  
• FDA approves Multaq to treat heart rhythm disorder  The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders).
  FDA July 02, 2009  
• Johnson & Johnson and Elan Corporation announce definitive agreement  Johnson & Johnson and Elan Corporation announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company.
  Johnson & Johnson July 02, 2009  
• Graceway Pharmaceuticals acquires early-stage dermatological molecules from Pfizer  Graceway Pharmaceuticals and Pfizer announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.
  Pfizer Inc. July 01, 2009  
• FDA: Boxed warning on serious mental health events to be required for Chantix and Zyban  The U.S. Food and Drug Administration announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion).
  FDA July 01, 2009  
• Pfizer updates CHANTIX (R) (varenicline) labeling in the United States  Pfizer announced that it has updated the U.S. product labeling for CHANTIX(R) (varenicline), a prescription aid to smoking cessation treatment, to communicate important safety information in a boxed warning as well as in revised warnings and precautions.
  Pfizer Inc. July 01, 2009  
• Pfizer launches medicine assistance program for newly unemployed  An assistance program offered by Pfizer that can help unemployed Americans continue receiving their prescription medicines. The program is fully operational July 1.
  Pfizer Inc. July 01, 2009  
• Schering-Plough announces Phase II and III data for corifollitropin alfa  Schering-Plough announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
  Schering-Plough Corp. July 01, 2009  
• Washington Technology Center awards $376,454 to spur innovation and jobs  Washington Technology Center has awarded a total of $376,454 in state funding to five researchers working with companies to develop commercially promising technologies. The companies expect commercial adoption of their technologies to create 175 new jobs in Washington during the next five years.
  Washington Technology Center July 01, 2009  

   (next 10 articles)